This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Agile Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Agile Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	19.7%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Agile appoints chief commercial officer from within ranks amid leadership revamp

Oct 10

How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?

Feb 25

Agile Therapeutics issues cash projection at JP Morgan healthcare conference

Jan 14

Assessing Agile Therapeutics

Jan 10

How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?

Jan 04

Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch

Nov 30

Agile Therapeutics EPS in-line

Nov 12

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Agile Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:AGRX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	22	-16	-2	-2	N/A
3/31/2024	21	-8	-10	-10	N/A
12/31/2023	20	-14	-10	-10	N/A
9/30/2023	20	-14	-11	-11	N/A
6/30/2023	16	-19	-28	-28	N/A
3/31/2023	13	-20	-23	-23	N/A
12/31/2022	11	-25	-36	-36	N/A
9/30/2022	8	-41	-51	-51	N/A
6/30/2022	7	-52	-53	-53	N/A
3/31/2022	6	-64	-66	-65	N/A
12/31/2021	4	-71	-65	-65	N/A
9/30/2021	3	-69	-66	-66	N/A
6/30/2021	2	-68	-63	-63	N/A
3/31/2021	1	-61	-54	-54	N/A
12/31/2020	1	-52	-48	-47	N/A
9/30/2020	N/A	-40	-34	-33	N/A
6/30/2020	N/A	-29	-23	-23	N/A
3/31/2020	N/A	-22	-19	-19	N/A
12/31/2019	N/A	-19	-16	-16	N/A
9/30/2019	N/A	-16	-16	-16	N/A
6/30/2019	N/A	-16	-14	-14	N/A
3/31/2019	N/A	-18	-16	-16	N/A
12/31/2018	N/A	-20	-17	-17	N/A
9/30/2018	N/A	-22	-20	-20	N/A
6/30/2018	N/A	-26	-24	-23	N/A
3/31/2018	N/A	-28	N/A	-24	N/A
12/31/2017	N/A	-28	N/A	-25	N/A
9/30/2017	N/A	-27	N/A	-22	N/A
6/30/2017	N/A	-28	N/A	-22	N/A
3/31/2017	N/A	-29	N/A	-23	N/A
12/31/2016	N/A	-29	N/A	-23	N/A
9/30/2016	N/A	-27	N/A	-25	N/A
6/30/2016	N/A	-29	N/A	-25	N/A
3/31/2016	N/A	-29	N/A	-27	N/A
12/31/2015	N/A	-30	N/A	-25	N/A
9/30/2015	N/A	-33	N/A	-26	N/A
6/30/2015	N/A	-30	N/A	-26	N/A
3/31/2015	N/A	-25	N/A	-21	N/A
12/31/2014	N/A	-16	N/A	-15	N/A
9/30/2014	N/A	-12	N/A	-11	N/A
6/30/2014	N/A	-9	N/A	-7	N/A
3/31/2014	N/A	-10	N/A	-8	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AGRX's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if AGRX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if AGRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if AGRX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AGRX's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AGRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/08/26 02:44
End of Day Share Price	2024/08/26 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Agile Therapeutics, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Chiara Russo	Cantor Fitzgerald & Co.
Colin Scarola	CFRA Equity Research
Edward White	FBR Capital Markets & Co.

This company has been acquired

Agile Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023

Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023

Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Recent updates

Exeltis USA, Inc. completed the acquisition of Agile Therapeutics, Inc. (OTCPK:AGRX) from Beryl Capital Management LLC and others.

Agile Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $15 million.

Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. (OTCPK:AGRX) for $10.7 million.

Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Index

Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite Index

Nasdaq to Suspend Common Stock of Agile Therapeutics Effective March 26

Agile Therapeutics, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Agile Therapeutics, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023

Agile Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Agile Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Agile Therapeutics Announces Update on Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Agile Therapeutics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023

Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX).

Agile Therapeutics Receives an Additional 180-Day Period, or Until September 25, 2023 from Nasdaq, to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Agile Therapeutics, Inc. has completed a Follow-on Equity Offering.

Agile Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Agile Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Agile appoints chief commercial officer from within ranks amid leadership revamp

Agile Therapeutics Announces Reorganization of Leadership Team

Agile Therapeutics, Inc. Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Agile Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Agile gains as H.C. Wainwright sees 630% upside potential

Agile Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.

Agile Therapeutics prices $24M upsized stock offering

Agile Therapeutics, Inc. to Appoint Jason Butch as Principal Financial Officer

Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation

Agile Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

Agile Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy

Agile Therapeutics, Inc. Contemplates Bankruptcy

Agile Therapeutics: Bullish On Capitulation And Max Pain

Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy

Agile Therapeutics, Inc.(NasdaqCM:AGRX) dropped from Russell 3000E Growth Index

Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting